keyword
MENU ▼
Read by QxMD icon Read
search

SLE review

keyword
https://www.readbyqxmd.com/read/29451069/arthritis-and-use-of-hydroxychloroquine-associated-with-a-decreased-risk-of-macrophage-activation-syndrome-among-adult-patients-hospitalized-with-systemic-lupus-erythematosus
#1
E M Cohen, K D'Silva, D Kreps, M B Son, K H Costenbader
Background Macrophage activation syndrome (MAS) is an uncommon but serious complication of systemic lupus erythematosus (SLE). We aimed to identify factors associated with MAS among adult hospitalized SLE patients. Methods Within the Brigham and Women's Hospital (BWH) Lupus Center Registry, we identified adult SLE patients > age 17 who had been hospitalized from 1970 to 2016, with either ferritin > 5000 ng/ml during admission or "macrophage activation syndrome" or "MAS" in discharge summary...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29448881/outcomes-of-multitarget-therapy-using-mycophenolate-mofetil-and-tacrolimus-for-refractory-or-relapsing-lupus-nephritis
#2
C-B Choi, S Won, S-C Bae
Objectives Outcomes of systemic lupus erythematosus (SLE) have significantly improved over the years. However, when there is major organ involvement, the outcomes can still be unfavorable. Outcomes of multitarget therapy using mycophenolate mofetil (MMF) and tacrolimus in patients with SLE who were refractory to standard therapy were assessed. Methods We retrospectively reviewed the Hanyang BAE lupus cohort to identify patients with biopsy-confirmed lupus nephritis (classes III, IV, or V) who failed to either achieve complete response with standard induction therapy or those who had a lupus flare after achieving a complete response with conventional induction therapy and subsequently were switched to multitarget combination therapy with MMF and tacrolimus...
January 1, 2018: Lupus
https://www.readbyqxmd.com/read/29444467/olfactory-function-in-systemic-lupus-erythematosus-and-systemic-sclerosis-a-longitudinal-study-and-review-of-the-literature
#3
REVIEW
Mariana Freschi Bombini, Fernando Augusto Peres, Aline Tamires Lapa, Nailú Angélica Sinicato, Beatriz Ricato Quental, Ágatha de Souza Melo Pincelli, Tiago Nardi Amaral, Caroline Cristina Gomes, Ana Paula Del Rio, João Francisco Marques-Neto, Lilian T L Costallat, Paula Teixeira Fernandes, Fernando Cendes, Leticia Rittner, Simone Appenzeller
BACKGROUND/PURPOSE: To evaluate olfactory function in systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and healthy controls over a 2-year period, and to determine the association of olfactory dysfunction with age, disease activity, disease damage, treatment, anxiety and depression symptoms and limbic structures volumes. METHODS: Consecutive SLE and SSc patients were enrolled in this study. Clinical, laboratory disease activity and damage were assessed according to diseases specific guidelines...
February 11, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29438163/the-interplay-between-tuberculosis-and-systemic-lupus-erythematosus
#4
Gustavo Guimarães Moreira Balbi, Francinne Machado-Ribeiro, Cláudia D L Marques, Flávio Signorelli, Roger Abramino Levy
PURPOSE OF REVIEW: Tuberculosis (TB) is a millenarian chronic infection and, yet, remains a major global health problem. The interaction between systemic lupus erythematosus (SLE) and TB is complex, as one seems to be a risk factor for the development of the other. SLE patients are more likely to develop TB, that is more frequently extrapulmonary, with more extensive pulmonary involvement, and with a higher relapse rate. RECENT FINDINGS: Different studies suggest that TB is more prevalent in SLE patients and that TB may actually be a risk factor for the development of the disease...
February 12, 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29428197/therapeutic-impact-of-statins-on-the-lipid-profile-and-cardiovascular-risk-in-patients-with-systemic-lupus-erythematosus-systematic-review-of-the-literature-and-a-meta-analysis
#5
Paula Sánchez, Esteban Toro-Trujillo, Oscar M Muñoz-Velandia, Angel Alberto García, Daniel G Fernández-Ávila
BACKGROUND: There is strong evidence of a rise in cardiovascular risk in patients suffering from autoimmune diseases, especially in those with Sistemic Lupus Erythematosus. Until now, there are a few trials that assess the potencial benefit of statins on the incidence of cardiovascular events and on lipid profile of patients with SLE. This evidence has not been synthesized and assessed altogether. METHODS: We performed a search in databases of literature published until August of 2016 (Embase, MEDLINE, Cochrane Library, SciELO, Clinical Evidence, DynaMed, Cochrane Central Register of Controlled Trials, LILACS), identifying controlled clinical trials that could estimate the impact of statins on mortality, cardiovascular events, C-reactive protein and lipid profile in patients with Systemic Lupus Erythematosus...
February 7, 2018: Reumatología Clinica
https://www.readbyqxmd.com/read/29427827/nailfold-capillaroscopy-in-systemic-lupus-erythematosus-a-systematic-review-and-critical-appraisal
#6
REVIEW
Maurizio Cutolo, Karin Melsens, Sara Wijnant, Francesca Ingegnoli, Kristof Thevissen, Filip De Keyser, Saskia Decuman, Ulf Müller-Ladner, Yves Piette, Valeria Riccieri, Nicola Ughi, Els Vandecasteele, Amber Vanhaecke, Vanessa Smith
Nailfold capillaroscopy is an easy, non-invasive technique to assess microvascular involvement in rheumatic diseases. Multiple studies describe capillaroscopic changes in systemic lupus erythematosus (SLE), including a wide range of non-specific findings. On behalf of the European League Against Rheumatism (EULAR) study group on microcirculation in rheumatic diseases, a systematic review was done to obtain all original research studies (in English) in which SLE patients had capillaroscopy. Forty such studies are identified...
February 7, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29426575/systematic-review-and-meta-analysis-of-steroid-sparing-effect-of-biologic-agents-in-randomized-placebo-controlled-phase-3-trials-for-systemic-lupus-erythematosus
#7
REVIEW
Shereen Oon, Molla Huq, Timothy Godfrey, Mandana Nikpour
OBJECTIVES: To systematically review, and conduct a meta-analysis of steroid-sparing effect in, phase 3 randomized, placebo-controlled trials of biologic therapies for systemic lupus erythematosus (SLE). METHODS: Studies were identified by searching Medline (via Pubmed), EMBASE, CINAHL and SCOPUS databases, the Cochrane library, and clinicaltrials.gov. Adult human studies published in English in the last ten years (until 18/04/2017) were included. A random-effects meta-analysis comparing a common corticosteroid-reduction endpoint in the trials of rituximab, belimumab, tabalumab and epratuzumab in SLE, was conducted...
January 6, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29425937/ige-in-lupus-pathogenesis-friends-or-foes
#8
REVIEW
Jean-François Augusto, Marie-Elise Truchetet, Nicolas Charles, Patrick Blanco, Christophe Richez
Systemic lupus erythematosus (SLE) is a complex autoimmune disease involving multiple immunological pathways. Recently, several studies have suggested an implication of Immunoglobulin E (IgE) in the pathophysiology of SLE. In the Lyn-/- and FcγIIB-/-.Yaa lupus mouse models, autoreactive IgE activate basophils, and promote a Th2 environment with, subsequently, production of autoantibodies by plasma cells. Autoreactive IgE has been also shown to play a role in the activation of human plasmacytoid dendritic cells (pDCs), in synergy with IgG, which results in an increase of interferon-alpha (IFN-α) production...
February 6, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29413506/pulmonary-arterial-hypertension-in-the-setting-of-scleroderma-is-different-than-in-the-setting-of-lupus-a-review
#9
REVIEW
Isabel S Bazan, Kofi A Mensah, Anastasiia A Rudkovskaia, Percy K Adonteng-Boateng, Erica L Herzog, Lenore Buckley, Wassim H Fares
Pulmonary hypertension (PH) is a clinical syndrome that is subdivided into five groups per the World Health Organization (WHO) classification, based largely on hemodynamic and pathophysiologic criteria. WHO Group 1 PH, termed pulmonary arterial hypertension (PAH), is a clinically progressive disease that can eventually lead to right heart failure and death, and it is hemodynamically characterized by pre-capillary PH and increased pulmonary vascular resistance in the absence of elevated left ventricular filling pressures...
January 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29408771/headache-in-mitochondrial-disorders
#10
REVIEW
Josef Finsterer, Sinda Zarrouk-Mahjoub
Headache is a prominent feature in mitochondrial disorders (MIDs) but no comprehensive overview is currently available. This review aims at summarising and discussing findings concerning type, frequency, pathogenesis, and treatment of headache in MIDs. The most frequent headache types in MIDs are migraine and migraine-like headache (MLH). MLH is classified as secondary headache. More rarely, tension-type headache, trigemino-autonomic headache, or different secondary headaches can be found. Migraine or MLH may manifest with or without aura...
January 26, 2018: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29396833/belimumab-a-review-in-systemic-lupus-erythematosus
#11
Hannah A Blair, Sean T Duggan
Belimumab (Benlysta®) is a human immunoglobulin G1λ monoclonal antibody that inhibits the binding of soluble B lymphocyte stimulator to B cells. It is the only biological agent currently approved for the treatment of non-renal systemic lupus erythematosus (SLE). Belimumab is approved in the EU, the USA and other countries as add-on therapy in adult patients with active, autoantibody-positive SLE despite standard therapy. In phase III trials, treatment with IV or SC belimumab plus standard therapy was effective in terms of reducing overall disease activity and reducing the incidence and severity of flares, without worsening of patients' overall condition or the development of significant disease activity in new organ systems...
February 2, 2018: Drugs
https://www.readbyqxmd.com/read/29395255/lessons-learned-from-bone-marrow-failure-in-systemic-lupus-erythematosus-case-reports-and-review-of-the-literature
#12
Erik Anderson, Bhakti Shah, Anne Davidson, Richard Furie
OBJECTIVE: In the present review, four new cases of bone marrow failure are presented and the potential contribution of systemic lupus erythematosus (SLE) is discussed. Furthermore, a comprehensive literature review of cases of autoimmune myelofibrosis (AIMF), aplastic anemia (AA), and paroxysmal nocturnal hemoglobinuria (PNH) with concurrent SLE aims to allow their direct comparison. Based on a clearer characterization of reported cases and our own experience, diagnostic and therapeutic strategies of these disorders in SLE are proposed based on lessons learned from the present and previous cases...
December 8, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29392731/immune-modulatory-effects-of-statins
#13
REVIEW
Robert Zeiser
Despite major advances in recent years, immunosuppressive regimens for multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and graft-versus-host disease (GVHD) have still major side effects and immunomodulation rather than immune paralysis would be desirable. Statins inhibit the rate limiting enzyme of the L-mevalonate pathway, the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase. It was shown that blocking the L-mevalonate pathway reduces inflammation via effects on downstream metabolites of the pathway including farnesylpyrophosphates and geranylgeranylpyrophosphates which are essential for the attachment of GTPases like RhoA, Rac and Ras to the cell membrane...
February 2, 2018: Immunology
https://www.readbyqxmd.com/read/29390513/concomitant-systemic-lupus-erythematosus-and-hiv-infection-a-rare-case-report-and-literature-review
#14
Hong-Yan Liao, Chuan-Min Tao, Jun Su
RATIONALE: Coexisting systemic lupus erythematosus (SLE) and human immunodeficiency virus (HIV) infection cases are rare worldwide. Great challenges are posed on the diagnosis and treatment of such concurrent cases. PATIENT CONCERN: We report the case of a 44-year-old Chinese man with edema, hematuria, and fever who presented at West China Hospital, Sichuan University, Chengdu, Sichuan, China, in 2013. DIAGNOSES: An initial diagnosis of SLE was made from the clinical manifestations and laboratory findings based on the Systemic Lupus International Collaborating Clinics classification criteria...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29387436/very-delayed-lupus-nephritis-a-report-of-three-cases-and-literature-review
#15
André R Alexandre, Pedro L Carreira, David A Isenberg
Lupus nephritis (LN) affects up to 50% of patients with Systemic Lupus Erythematosus (SLE) and is associated with a worse prognosis. LN usually develops within the first 5 years of the onset of the disease. We report three patients with very delayed LN (DLN) diagnosed after 15 or more years after SLE diagnosis. The three patients were non-Caucasian women with adolescent or adult-onset SLE. Each had antinuclear, anti-dsDNA and anti-Ro antibodies. Hydroxychloroquine was prescribed for each. Their disease courses were characterised by sporadic non-renal flares controlled by steroids and, in two cases, by one cycle of rituximab...
2018: Lupus Science & Medicine
https://www.readbyqxmd.com/read/29366725/performance-of-the-2012-systemic-lupus-international-collaborating-clinics-classification-criteria-versus-the-1997-american-college-of-rheumatology-classification-criteria-in-adult-and-juvenile-systemic-lupus-erythematosus-a-systematic-review-and-meta-analysis
#16
REVIEW
Esther A R Hartman, Annet van Royen-Kerkhof, Johannes W G Jacobs, Paco M J Welsing, Ruth D E Fritsch-Stork
OBJECTIVE: To evaluate the performance in classifying systemic lupus erythematosus by the 2012 Systemic Lupus International Collaborating Clinics criteria (SLICC'12), versus the revised American College of Rheumatology criteria from 1997 (ACR'97) in adult and juvenile SLE patients. METHODS: A systematic literature search was conducted in PubMed and Embase for studies comparing SLICC'12 and ACR'97 with clinical diagnosis. A meta-analysis was performed to estimate the sensitivity and specificity of SLICC'12 and ACR'97...
January 21, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29361147/glucocorticoid-use-and-factors-associated-with-variability-in-this-use-in-the-systemic-lupus-international-collaborating-clinics-inception-cohort
#17
Jayne Little, Ben Parker, Mark Lunt, John G Hanly, Murray B Urowitz, Ann E Clarke, Juanita Romero-Diaz, Caroline Gordon, Sang-Cheol Bae, Sasha Bernatsky, Daniel J Wallace, Joan T Merrill, Jill Buyon, David A Isenberg, Anisur Rahman, Ellen M Ginzler, Michelle Petri, Mary Anne Dooley, Paul Fortin, Dafna D Gladman, Kristjan Steinsson, Rosalind Ramsey-Goldman, Munther A Khamashta, Cynthia Aranow, Meggan Mackay, Graciela S Alarcón, Susan Manzi, Ola Nived, Andreas Jönsen, Asad A Zoma, Ronald F van Vollenhoven, Manuel Ramos-Casals, Guillermo Ruiz-Irastorza, Sung Sam Lim, Kenneth C Kalunian, Murat Inanc, Diane L Kamen, Christine A Peschken, Soren Jacobsen, Anca Askanase, Jorge Sanchez-Guerrero, Ian N Bruce
Objectives: To describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent physician-related factors may influence use. Methods: Patients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999 and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors associated with GC use at enrolment and over time...
January 18, 2018: Rheumatology
https://www.readbyqxmd.com/read/29353100/vitamin-d-and-juvenile-systemic-lupus-erythematosus-lights-shadows-and-still-unresolved-issues
#18
REVIEW
Stefano Stagi, Donato Rigante
Systemic lupus erythematosus (SLE) and juvenile SLE (jSLE) are autoimmune disorders naturally associated with several genetic, environmental, hormonal, and immunological contributing factors. It has been assumed that vitamin D deficiency may have a role in the immune activation of patients with SLE and play an active part in many comorbidities and even complications. A host of clinical studies suggested that vitamin D exerts inhibitory effects on many immunological abnormalities associated with SLE, also in children and adolescents, while different reports have hypothesized that vitamin D may be associated with accelerated cardiovascular disease in SLE...
January 15, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29335347/smoking-is-the-most-significant-modifiable-lung-cancer-risk-factor-in-systemic-lupus-erythematosus
#19
Sasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, Murray B Urowitz, Dafna D Gladman, Paul R Fortin, Edward H Yelin, Ellen Ginzler, John G Hanly, Christine Peschken, Caroline Gordon, Ola Nived, Cynthia Aranow, Sang-Cheol Bae, David Isenberg, Anisur Rahman, James E Hansen, Yvan St Pierre, Ann E Clarke
OBJECTIVE: To assess lung cancer risk in systemic lupus erythematosus (SLE), relative to demographics, drug exposures, smoking, and disease activity. METHODS: We analyzed data from 14 SLE cohorts. We calculated adjusted HR estimates for lung cancer in SLE, relative to demographics, smoking, time-dependent medication exposures, and cumulative disease activity [mean adjusted SLE Disease Activity Index (SLEDAI) scores]. This project was approved by the ethics boards of all participating institutions, including the Institutional Review Board of the McGill University Health Centre...
January 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29326157/targeting-b-cells-and-plasma-cells-in-glomerular-diseases-translational-perspectives
#20
Eva Schrezenmeier, David Jayne, Thomas Dörner
The unique contributions of memory B cells and plasma cells in kidney diseases remain unclear. In this review, we evaluate the clinical experience with treatments directed at B cells, such as rituximab, and at plasma cells, such as proteasome inhibition, to shed light on the role of these two B lineage compartments in glomerular diseases. Specifically, analysis of these targeted interventions in diseases such as ANCA-associated vasculitis, SLE, and antibody-mediated transplant rejection permits insight into the pathogenetic effect of these cells...
January 11, 2018: Journal of the American Society of Nephrology: JASN
keyword
keyword
120284
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"